The Latest Analyst Ratings For Legend Biotech
Portfolio Pulse from Benzinga Insights
In the past three months, 15 analysts have provided ratings for Legend Biotech (NASDAQ: LEGN), with the majority being bullish. The average 12-month price target has decreased slightly to $78.93. Analysts have varied in their actions, with some lowering their price targets while others maintain or raise their ratings. Legend Biotech has shown significant revenue growth but struggles with profitability and returns.
July 15, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Legend Biotech has received mixed analyst ratings over the past three months, with a slight decrease in the average 12-month price target to $78.93. The company has shown strong revenue growth but faces challenges in profitability and returns.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on Legend Biotech's stock price. While the company has shown strong revenue growth, its challenges in profitability and returns may offset positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100